Anhydrous reverse micelle lecithin nanoparticles/PLGA composite microspheres for long-term protein delivery with reduced initial burst

Chen, Longkai; Mei, Liling; Feng, Disang; Huang, Di; Tong, Xin; Pan, Xin; Zhu, Chune; Wu, Chuanbin

doi:10.1016/j.colsurfb.2017.12.040

Cited by 30 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous research of our group, about PLGA microparticles reduced initial burst of protein by loading protein in lecithin nanoparticles in advance. The SEM images of PLGA microparticle incubated in release medium for 2 months could also help to explain the performance and penetration rate of nanoparticles . Specifically, lecithin nanoparticles not only supported the homogenous distribution of payload and reduce the distribution on the surface of microspheres, but also assisted to the faster degradation of carriers.…”

Section: Resultsmentioning

confidence: 99%

“…Encapsulating the drug into composite microspheres might be an effective strategy for controlled drug release . This work aimed to develop SLN/PLGA composite microspheres by an S/W/O/W method to reduce the initial burst release and achieve the sustained release of AFT through initially encapsulating AFT into SLN.…”

Section: Resultsmentioning

confidence: 99%

“…Preparation of AFT‐SLN‐PTX‐pMS : AFT‐SLN‐ and PTX‐loaded PLGA large porous particles (AFT‐SLN‐PTX‐pMS) were prepared by a modified multiple emulsion (S/W/O/W) solvent evaporation method as described previously 16c,17. The simple preparation process of AFT‐SLN‐PTX‐pMS can be seen in Figure B.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer

Yang

Huang

Jin-yuan

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome resistance that often occurs after 9–13 months of EGFR TKIs administration in nonsmall cell lung cancer (NSCLC). In this study, a pulmonary microspheres system that codelivers afatinib and paclitaxel (PTX) is developed for treatment of EGFR TKIs resistant NSCLC. In this system, afatinib is loaded in stearic acid‐based solid lipid nanoparticles, then these nanoparticles and PTX are loaded in poly‐lactide‐co‐glycolide‐based porous microspheres. These inhaled microspheres systems are characterized including geometric particle size, drug encapsulation efficiency, morphology by scanning electron microscopy, specific surface area, in vitro drug release, and aerodynamic particle size. Cell experiments indicate that afatinib and PTX have a synergistic effect and the codelivery system shows a superior treatment effect in drug‐resistant NSCLC cells. The biocompatibility, pharmacokinetic, and tissue distribution experiments in Sprague–Dawley rats show that afatinib and PTX in the system can maintain 96 h of high lung concentration but low concentration in other tissues, with acceptable safety. These results demonstrate that this system may be a prospective delivery strategy for drug combination treatment in cancers developing resistance, especially drug‐resistant lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer

Yang

Huang

Jin-yuan

et al. 2019

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…1,2 The sustained release of a drug from PLGAmicrosphere (MS) is caused by the hydrolysis of its ester linkages in the presence of water according to the lactic acid and glycolic acid ratio. 5 This resulted in the release of the drug being completed between 1 and 3 days. 5 This resulted in the release of the drug being completed between 1 and 3 days.…”

Section: Introductionmentioning

confidence: 99%

PLGA Microsphere Addition to 1‐Hydroxy‐2‐napthoic Acid Enhances the Sustained Release of Escitalopram

Kang

Kim

Kwon

et al. 2019

Bulletin Korean Chem Soc

View full text Add to dashboard Cite

Escitalopram (ET), a selective serotonin reuptake inhibitor, has been utilized for the treatment of depression and anxiety. However, ET has serious side effects such as nausea, leading to an increased therapeutic dose, needing multiple administrations. Therefore, to overcome these issues, we developed ET encapsulated poly (d,l-lactic-co-glycolic acid) (PLGA) microspheres (PLGA-MS) as a sustained release carrier to maintain therapeutic efficacy. The mean particle size of the PLGA-MSs was measured by microscopy. Loading efficiency was measured by high performance liquid chromatography (HPLC). Morphologies were determined by microscopy and scanning electron microscopy (SEM). Differential scanning calorimetry (DSC) was used for thermal analysis and glass transition temperature determination. Mean particle size of the ET-loaded PLGA-MSs was 129 AE 14 μm, loading efficiency was 36.8 AE 9.1%, and encapsulation efficiency was up to 70.6 AE 6.8%. Loading efficiency and encapsulation efficiency were increased by the addition of 1-hydroxy-2-naphthoic acid (HNA). ET was released from PLGA-MS for 4 weeks, which was longer than ET release from PLGA-MS without the addition of HNA. Taken together, we demonstrate the optimum condition for sustained release of ET from PLGA-MS with the addition of HNA, and that this approach may be useful for depression therapy.

show abstract

“…of proteins and peptides. However, it suffers some limitations necessitating some careful considerations particularly in context to the dispersion stability as well as stability of loaded bioactive(s) [32][33][34]. Moreover, these limitations can effectively be addressed via surface modification of the system using various strategies including encapsulation of stimuli responsiveness where in the stimuli are largely pH, temperature, redox potential, light and magnetic field, etc.…”

Section: Introductionmentioning

confidence: 99%

Release promoter-based systematically designed nanocomposite(s): a novel approach for site-specific delivery of tumor-associated antigen(s) (TAAs)

Sharma

Dubey

Mody

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The aim of present approach was to design and develop mannose functionalized reverse polymeric nanocomposite(s) system based on release promoter (MRPRPNs). Thus, the composition of the present formulation was optimized by employing the systematic design of experiments (DoE) for screening and optimization using L8-Array Taguchi and 3-level-3-factor Box-Behnken Design (BBD). Further, the developed formulation was observed for its preferential internalization by professional antigen presenting cells (macrophages/dendritic cells) and prompt release of loaded antigen in a pH-dependent manner. The optimized formulation was also extensively characterized for average hydrodynamic diameter, surface potential, poly dispersity index of reverse polymeric nanocomposite(s) which were recoded to be 189.4 ± 8.52 nm, 0.111 ± 0.024, -23.4 ± 2.0 mV, respectively; while percentage entrapment efficiency of OVA in MRPRPNs to be 60.17 ± 2.41%. The release pattern of OVA from MRPRPNs was consistent at pH 7.4. However, at acidic pH (≈5.5) where in protons (H) are in-filtered into the core of MRPRPNs thereby generating the pressure, resultantly causing and creating the pores or disruption of the system thus allowed a prompt release (≈60-70%) of encapsulated OVA from interior to outer milieu within 1 h. MRPRPNs were preferentially internalized through receptor-mediated endocytosis and released the loaded OVA into the cytosol of RAW 264.7 cells. From the above findings, it can be concluded that reverse polymeric system could significantly be loaded with immunobioactive(s) and could potentially deliver the contents at the specific site for the better therapeutic outcome.

show abstract

Anhydrous reverse micelle lecithin nanoparticles/PLGA composite microspheres for long-term protein delivery with reduced initial burst

Cited by 30 publications

References 28 publications

PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer

PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib‐Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer

PLGA Microsphere Addition to 1‐Hydroxy‐2‐napthoic Acid Enhances the Sustained Release of Escitalopram

Release promoter-based systematically designed nanocomposite(s): a novel approach for site-specific delivery of tumor-associated antigen(s) (TAAs)

Contact Info

Product

Resources

About